Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aesica Announces Partnership with Bradford University

Published: Monday, January 14, 2013
Last Updated: Monday, January 14, 2013
Bookmark and Share
Partnership will enable the Bradford team to utilize the GMP capabilities and assets held at Aesica.

Aesica has announced a partnership with the Centre for Pharmaceutical Engineering Science at the University of Bradford, which will enable the team at Bradford to utilize the GMP capabilities and assets held at Aesica, while Aesica will benefit from the Centre’s extensive research facilities.

The partnership was formed following a presentation from Dr. Riddhi Shukla, business development manager at the Centre for Pharmaceutical Engineering Science to the Aesica Innovation Board and builds upon the relationship established in 2009 between both parties.

The Centre offers a number of processing technologies including hot melt extrusion, but relies on the GMP expertise of the formulation development team at Aesica to manufacture GMP clinical trial supplies.

Speaking of the partnership, Paul Titley, managing director, Formulation Development, Aesica says: “We provide GMP contract manufacturing services to six other universities, but this partnership is particularly important and unique as it is mutually beneficial. While the team at Bradford has development expertise in several key approaches and as such can evaluate the viability of compounds presented by virtual and small pharma organizations, our GMP expertise is crucial to take the compounds into clinical trials, which is vital. By working with such organizations at an early stage we would hope to cement long term development and manufacturing partnerships and expedite the leap from concept to commercialization with a clear and proven route to market. In addition, the facilities at the Centre for Pharmaceutical Engineering Science will enable us to further enhance our overall formulation development service offering which will add value to our existing clients.”

Dr. Shukla adds: “Aesica is a well established pharmaceutical company with exemplary GMP credentials, which we were keen to tap into for the benefit of our contacts within the multinational pharma community. Our facilities at the Centre are second to none and we believe this coupled with our research expertise will deliver significant benefits to Aesica as the partnership evolves.”

The partnership follows a sustained period of expansion by Aesica, which has seen the CMO double its workforce and establish three manufacturing sites in Europe and drive forward plans to expand its offer across America.

In addition, Aesica has recently announced plans to create up to 100 new jobs at its Queenborough, UK, facility between now and 2015 as the site prepares for significant expansion.

Furthermore, the company was recently ranked in The Sunday Times HSBC International Track 200, a newly created list that ranks Britain’s private companies with the fastest growing international sales.

Published in July, the table listed Aesica as the second best performing company in the North East of England after its international sales grew by 37 per cent over the course of the two years to December 2011 - international sales now represent 98 per cent of the company’s overall turnover.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aesica Secures Continuing FDA Approval of its Bulk Manufacture and Packaging Sites
FDA inspection results means Aesica will continue to grow its manufacturing and packaging services for pharmaceutical products for the US market.
Tuesday, February 03, 2015
Aesica Appoints VP, Business Development and Business Development Director
Appointment of Detlef Behrens and Sven Wrabletz for finished dose to drive service in Europe and achieve further growth.
Friday, October 31, 2014
Aesica Appoints New Product Release Manager
Company announces appointment of Adam Burgess.
Wednesday, August 20, 2014
Aesica Zwickau Marks 20th Anniversary
Continued growth and expansion of Company’s encapsulation services business.
Saturday, July 19, 2014
Aesica Recruits New Business Development Manager
Appointment of Nadine K. Reuter to aid sales drive across German, Austrian and Swiss Markets.
Thursday, July 03, 2014
Aesica Collaborates with QAD to Meet CFDA’s Shortened Serialization Deadline
The new system was implemented within three months.
Saturday, June 28, 2014
Aesica Successfully Introduces Serialization Services at Italian Site
Initiates commercial production of two product lines for the Chinese market.
Thursday, April 17, 2014
Aesica Led Consortium Wins Technology Strategy Board Grant
Funding secured for the consortium’s project to investigate an industrial biotechnology process to enable improved manufacture of an API.
Tuesday, April 08, 2014
Aesica Completes the Validation of its High Capacity Manufacturing Facility
$45m (USD) has been invested at its Queenborough, UK site.
Saturday, March 15, 2014
Aesica Appoints Ian Muir to Commercial Managing Director Position
Key functions centre on the Group’s commercial business and product pipeline development across API, formulation development and formulated products.
Tuesday, February 04, 2014
Aesica Awarded NEPIC Industry Award
Corporate HR Manager wins NEPIC 2014 Young Achiever Accolade within the Pharmaceutical category.
Thursday, January 30, 2014
Aesica Appoints New Site Manufacturing Manager at Cramlington Facility
Tasked with optimizing performance schedules, including 4 new products for 2014.
Tuesday, November 26, 2013
Aesica Recruits New East Coast Business Development Manager
Appointment of Baali Muganga to spearhead growth in contract manufacturing market share across the US region.
Tuesday, October 29, 2013
Aesica Target Development Services at Growing Inhalation Market
CDMO’s Nottingham site a hot bed of innovation with unique spray drying, powder filling and dry powder inhaler technology.
Wednesday, October 16, 2013
Aesica Unveils a New High Capacity Manufacturing Facility
New facility specifically built to produce a solid dose medication for treating Type 2 diabetes in adults.
Thursday, September 19, 2013
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!